CAMP4 Therapeutics (NASDAQ:CAMP) Downgraded to “Strong Sell” Rating by Zacks Research

Zacks Research cut shares of CAMP4 Therapeutics (NASDAQ:CAMP) from a hold rating to a strong sell rating in a research report released on Wednesday,Zacks.com reports.

A number of other brokerages also recently commented on CAMP. Leerink Partners raised their price objective on shares of CAMP4 Therapeutics from $8.00 to $9.00 and gave the company an “outperform” rating in a research report on Thursday, April 2nd. JPMorgan Chase & Co. upgraded CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $5.00 to $9.00 in a research report on Tuesday, June 16th. Chardan Capital set a $6.50 target price on CAMP4 Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, June 10th. Rodman & Renshaw assumed coverage on CAMP4 Therapeutics in a report on Tuesday, April 14th. They issued a “buy” rating and a $7.00 price target for the company. Finally, Weiss Ratings downgraded CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, May 21st. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.36.

CAMP4 Therapeutics Stock Performance

Shares of CAMP4 Therapeutics stock opened at $3.90 on Wednesday. The company has a market cap of $202.53 million, a P/E ratio of -1.65 and a beta of 0.10. CAMP4 Therapeutics has a one year low of $1.32 and a one year high of $7.75. The firm has a fifty day moving average of $4.28 and a two-hundred day moving average of $4.56.

CAMP4 Therapeutics (NASDAQ:CAMP) last issued its earnings results on Thursday, May 7th. The Wireless communications provider reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.11). CAMP4 Therapeutics had a negative net margin of 2,193.72% and a negative return on equity of 194.74%. The firm had revenue of $1.29 million during the quarter. As a group, equities analysts predict that CAMP4 Therapeutics will post -0.84 earnings per share for the current year.

Institutional Investors Weigh In On CAMP4 Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Vivo Capital LLC acquired a new position in CAMP4 Therapeutics during the third quarter worth $11,765,000. Balyasny Asset Management L.P. acquired a new position in shares of CAMP4 Therapeutics during the 4th quarter worth $14,938,000. Janus Henderson Group PLC boosted its position in shares of CAMP4 Therapeutics by 35.9% in the 4th quarter. Janus Henderson Group PLC now owns 6,307,636 shares of the Wireless communications provider’s stock worth $38,807,000 after buying an additional 1,666,666 shares in the last quarter. SummitTX Capital L.P. acquired a new stake in CAMP4 Therapeutics in the 1st quarter valued at about $1,497,000. Finally, EcoR1 Capital LLC purchased a new position in CAMP4 Therapeutics during the 4th quarter valued at about $1,992,000.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.